BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

BCRX 14.90 -0.58 (-3.75%)
price chart
Durham's BioCryst cuts $45 million deal with Australian firm
Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq: BCRX) licensed its recently approved flu treatment Rapivap in a deal that could bring the company $45 million plus sales royalties.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has licensed RAPIVAB (peramivir ...  Inside Trade
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza ...  GlobeNewswire (press release)
BioCryst Pharmaceuticals Raised to "Hold" at Zacks (BCRX)
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections.
Biocryst Pharmaceuticals Inc (BCRX) Files Form 4 Insider Selling : Thomas R Ii ...
Biocryst Pharmaceuticals Inc (BCRX): Thomas R Ii Staab , Senior Vice President and CFO of Biocryst Pharmaceuticals Inc sold 3,500 shares on Jul 20, 2015. The Insider selling transaction was disclosed on Jul 22, 2015 to the Securities and Exchange ...
Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a predominantly clinical-stage biotech company focused on developing novel small molecule drugs to treat varying diseases, scorched higher by as much as 12% in Wednesday's trading session ...
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Adds 5.4%  Zacks.com
Ebola Finances Coming Back in the News  24/7 Wall St.
Zacks Rating on BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) remains a strong buy in the latest set of rankings. The shares have received an average rating of 1.29 by 7 analysts.
Warning BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) optimists! Thomas Staab ...
Thomas Staab, the Senior Vice President and CFO of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 15.34 +0.08 0.52% , unloaded 3,500 shares of the company, valued at $57,750 U.S Dollars, estimated based on $16.5 a share.
Analyst Price Target Update on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)  American Trade Journal
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Rating Update  Investor Newswire
BioCryst Pharmaceuticals, Inc. Short Interest Update
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), According to the latest information the short interest in BioCryst Pharmaceuticals, Inc. shot up by 0.8% or 95,847 shares. The final shorts are 16.9% of the total floated shares. The positions increased ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Stock Insider Sale - Jon ...  OctaFinance.com
BioCryst Pharmaceuticals Receives $15.83 Consensus Target Price from ...  Dakota Financial News
Biocryst Pharmaceuticals (BCRX) Is Today's Strong On High Volume Stock
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Trade-Ideas LLC identified Biocryst Pharmaceuticals ( BCRX) as a strong ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Analyst Rating Update
Biocryst Pharmaceuticals (NASDAQ:BCRX) has received a short term rating of sell from research analysts at Zacks with a rank of 4. The company has been rated an average of 1.29 by 7 Wall Street Analysts. 6 analysts have added the shares in their list of ...
Analyst Price Target Update on BioCryst Pharmaceuticals, Inc.  Insider Trading Report
BioCryst Pharmaceuticals Short Interest Down 19.9% in June (BCRX)  Mideast Time
Company Shares of BioCryst Pharmaceuticals, Inc. Rally 3.81%
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose by 3.81% in the past week and 3.01% for the last 4 weeks.
BioCryst Pharmaceuticals Given Consensus Rating of "Buy" by ...  sleekmoney
News Buzz - BioCryst Pharmaceuticals (BCRX), Anacor Pharmaceuticals (ANAC ...  Techsonian (press release)